Prostate cancer is the most common non-skin cancer among American men, with the American Cancer Society estimating roughly 300,000 new diagnoses each year. Yet in its earliest and most treatable stages, the symptoms of prostate cancer are often completely absent. The disease typically grows slowly and remains confined to the prostate gland for years before producing any noticeable changes. That paradox — a common cancer that hides in plain sight — makes understanding screening guidelines and warning signs genuinely important. For more on medical conditions, see our medical conditions guide.
What Is Prostate Cancer?
The prostate is a walnut-sized gland located just below the bladder and in front of the rectum. It surrounds the upper portion of the urethra — the tube that carries urine from the bladder out of the body — and produces seminal fluid that nourishes and transports sperm.
Prostate cancer develops when cells in the prostate begin growing uncontrollably. Most prostate cancers are adenocarcinomas, meaning they arise from the glandular cells that produce prostatic fluid. According to the National Cancer Institute, about one in eight men will be diagnosed with prostate cancer during his lifetime, though the vast majority are diagnosed with localized disease that has an excellent prognosis.
Early Symptoms of Prostate Cancer
Early-stage prostate cancer rarely causes symptoms. Most men with localized prostate cancer feel perfectly normal and have no reason to suspect anything is wrong. When symptoms do appear early, they are often related to the prostate’s proximity to the bladder and urethra.
Urinary Changes
Difficulty starting urination, a weak or interrupted urine stream, frequent urination (especially at night), and the feeling of not fully emptying the bladder can all be associated with prostate cancer. However, these symptoms are far more commonly caused by benign prostatic hyperplasia (BPH) — non-cancerous enlargement of the prostate that affects the majority of men over 50. The symptoms of prostate cancer and BPH can be indistinguishable based on symptoms alone, which is why diagnostic testing is essential.
Blood in Urine or Semen
Hematuria (blood in urine) or hematospermia (blood in semen) can occasionally be an early sign of prostate cancer. While these symptoms have many possible causes — including infection, inflammation, and benign conditions — they should always be evaluated by a physician.
Erectile Dysfunction
New-onset erectile dysfunction can sometimes be linked to prostate cancer, though it is much more commonly related to cardiovascular disease, diabetes, medications, or psychological factors. When erectile dysfunction occurs alongside urinary changes, evaluation of the prostate is reasonable.
Advanced Symptoms
When prostate cancer grows beyond the gland or spreads to distant sites, additional symptoms may develop.
Bone pain. Prostate cancer has a particular tendency to metastasize to bones — especially the spine, pelvis, ribs, and femur. Persistent, deep pain in these areas that doesn’t respond to typical musculoskeletal treatments can be a sign of metastatic disease. According to the Mayo Clinic, bone pain is one of the most common symptoms of advanced prostate cancer.
Unexplained weight loss. Unintentional loss of 10 or more pounds over a few months without changes in diet or exercise can signal advanced cancer of many types, including prostate cancer.
Leg weakness or numbness. If prostate cancer spreads to the spine and compresses the spinal cord, it can cause weakness, numbness, or tingling in the legs. This is a medical emergency that requires immediate evaluation.
Loss of bladder or bowel control. Spinal cord compression from metastatic prostate cancer can also affect bladder and bowel function. Any sudden change in continence should be evaluated urgently.
Pelvic discomfort. A sense of pressure or discomfort in the pelvic area can develop as the tumor grows beyond the prostate capsule and affects surrounding structures.
Screening: PSA Testing and Digital Rectal Exam
Because early prostate cancer is usually asymptomatic, screening is the primary method of early detection. The two main screening tools are the PSA (prostate-specific antigen) blood test and the digital rectal exam (DRE).
The PSA test measures a protein produced by the prostate. Elevated PSA levels can indicate cancer, but they can also result from BPH, prostatitis, recent ejaculation, or certain medications. A PSA level above 4.0 ng/mL is traditionally considered elevated, though some cancers occur at lower levels and many men with elevated PSA do not have cancer.
Screening guidelines vary among medical organizations. The U.S. Preventive Services Task Force recommends that men aged 55 to 69 discuss the benefits and harms of PSA screening with their doctors and make an individual decision. For men at higher risk — including African American men and those with a family history of prostate cancer — many experts recommend starting the conversation at age 40 to 45.
The American Urological Association recommends shared decision-making for men aged 55 to 69 and suggests that high-risk men discuss screening beginning at age 40. Screening is generally not recommended for men over 70 or those with a life expectancy of less than 10 years.
Treatment Options Overview
While this article focuses on symptoms and detection, understanding the treatment landscape helps contextualize why early detection matters. Treatment options for localized prostate cancer include active surveillance (monitoring slow-growing cancers without immediate treatment), radical prostatectomy (surgical removal of the prostate), and radiation therapy (external beam or brachytherapy). The choice depends on the cancer’s grade and stage, the patient’s age and health, and personal preferences about side effects.
Active surveillance is increasingly recommended for low-grade prostate cancers (Grade Group 1) because many of these cancers never progress to clinically significant disease during a man’s lifetime. This approach avoids the side effects of surgery and radiation — including urinary incontinence and erectile dysfunction — while maintaining close monitoring through regular PSA tests, MRIs, and periodic biopsies. According to the National Comprehensive Cancer Network, active surveillance is the preferred management strategy for very-low-risk and low-risk prostate cancers.
Risk Factors
Several factors influence prostate cancer risk.
Age. Prostate cancer risk increases substantially after age 50. About 60% of cases are diagnosed in men over 65.
Race and ethnicity. African American men have the highest prostate cancer incidence and mortality rates of any racial group in the United States — roughly 70% higher incidence and more than double the mortality rate compared to white men, according to the American Cancer Society.
Family history. Having a father or brother with prostate cancer roughly doubles your risk. Multiple affected relatives or early-onset disease in a family member increase the risk further. Inherited mutations in BRCA1 and BRCA2 genes also elevate risk.
Diet and lifestyle. Research suggests that diets high in processed meat and dairy and low in fruits and vegetables may modestly increase risk, though the evidence is not as strong as for other risk factors. Obesity is associated with more aggressive prostate cancer at diagnosis.
How Prostate Cancer Is Diagnosed
If screening or symptoms suggest prostate cancer, several diagnostic steps follow. An elevated PSA or abnormal DRE typically leads to further testing, which may include a repeat PSA test, a free-to-total PSA ratio (a higher free PSA percentage suggests benign disease), and newer biomarker tests like the 4Kscore, Prostate Health Index (PHI), or SelectMDx urine test. These help determine who truly needs a biopsy versus who can safely be monitored.
Multiparametric MRI (mpMRI) of the prostate has become an increasingly important tool. It can identify suspicious areas within the prostate and guide targeted biopsies, improving accuracy compared to traditional random biopsies. The PI-RADS scoring system rates the likelihood that an MRI finding represents clinically significant cancer. According to research published on PubMed, MRI-targeted biopsies detect more clinically significant cancers while reducing the detection of insignificant cancers compared to standard biopsy alone.
A prostate biopsy — typically a transrectal or transperineal ultrasound-guided procedure — remains the definitive diagnostic step. Tissue samples are examined by a pathologist and graded using the Gleason scoring system (or the newer Grade Group system), which indicates how aggressive the cancer cells appear under the microscope.
When to See a Doctor
See your primary care physician or urologist if you experience persistent urinary changes such as increased frequency, difficulty starting or stopping, or a noticeably weak stream. Blood in urine or semen, new erectile dysfunction, unexplained pelvic pain, or bone pain that doesn’t resolve should also prompt evaluation.
Even in the absence of symptoms, discuss prostate cancer screening with your doctor if you are 55 or older, 40 or older with a family history, or an African American man age 40 or older. Screening is a shared decision — your doctor can help you weigh the potential benefits of early detection against the risks of overdiagnosis and overtreatment.
When to seek emergency care: Call 911 or go to the nearest emergency room if you develop sudden inability to urinate, sudden leg weakness or numbness, or loss of bladder or bowel control — these may indicate spinal cord compression, which requires immediate treatment.
Living With a Prostate Cancer Diagnosis
A prostate cancer diagnosis can feel overwhelming, but understanding the spectrum of the disease helps put it in perspective. Many prostate cancers — particularly low-grade tumors — grow so slowly that they may never affect quality of life or longevity. The distinction between indolent (slow-growing) and aggressive prostate cancer is critical. Your Gleason score, PSA level, clinical stage, and MRI findings collectively determine your cancer’s risk category and guide the treatment approach.
For men on active surveillance, routine monitoring provides ongoing reassurance while avoiding unnecessary treatment side effects. For those who do need treatment, advances in surgical technique (nerve-sparing robotic prostatectomy), radiation therapy (SBRT, proton therapy), and hormonal therapy have significantly improved outcomes and reduced side effects compared to treatments available even a decade ago. Support groups, mental health resources, and open communication with your healthcare team are valuable throughout the process.
Frequently Asked Questions
Can you have prostate cancer with no symptoms?
Yes. Most men with early-stage prostate cancer have no symptoms at all. The disease is typically discovered through PSA screening or a digital rectal exam before any noticeable changes occur. This is why screening discussions with your doctor are important, especially if you have risk factors.
What is the survival rate for prostate cancer?
The five-year relative survival rate for localized and regional prostate cancer is nearly 100%. Even for all stages combined, the five-year survival rate exceeds 97%. Prostate cancer that has spread to distant sites has a lower but still meaningful five-year survival rate of approximately 34%, and treatments continue to improve.
Does an elevated PSA mean I have cancer?
Not necessarily. About 75% of men with an elevated PSA (above 4.0 ng/mL) do not have prostate cancer. BPH, prostatitis, recent physical activity, and other factors can elevate PSA levels. An elevated PSA is a signal for further evaluation — typically a repeat PSA, additional biomarker tests, or a prostate biopsy — not a diagnosis.
At what age should I start screening?
For average-risk men, the screening conversation typically begins at age 55. For men at higher risk — including African Americans and those with a first-degree relative diagnosed with prostate cancer — many guidelines suggest discussing screening as early as age 40 to 45. Screening is generally not recommended after age 70.
Is prostate cancer hereditary?
It can be. About 5% to 10% of prostate cancers are thought to be primarily caused by inherited genetic changes. BRCA2 mutations, Lynch syndrome, and HOXB13 mutations are associated with increased risk. If multiple men in your family have had prostate cancer — especially at a young age — genetic counseling may be recommended.
What to Do Next
The symptoms of prostate cancer are often silent in early stages, which makes proactive screening the most effective tool for early detection. If you’re in the recommended age range or have risk factors, start the conversation with your doctor about PSA testing. If you’re experiencing urinary changes, don’t assume it’s just aging or BPH — get evaluated to rule out cancer and other treatable conditions. Early-stage prostate cancer offers multiple treatment options and outstanding outcomes, but those advantages depend on catching it before symptoms force the diagnosis. For other cancer-related topics, explore our articles on symptoms of thyroid cancer and liver damage warning signs.